Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2959 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2959 | 0.5 |
Brugia malayi | hypothetical protein | 0.0035 | 0.2959 | 0.2209 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.2959 | 0.3753 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2951 | 0.4076 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0191 | 0.0242 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2959 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.724 | 1 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0535 | 0.0739 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 0.2959 | 0.4088 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4163 | 0.4395 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 0.2959 | 0.4088 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0535 | 0.0739 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2951 | 0.4076 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0535 | 0.0679 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.7886 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 0.2959 | 0.3753 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.3391 | 0.3541 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3818 | 0.4014 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.3378 | 0.2673 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.724 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.9228 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2959 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.